Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock Holdings Increased by Cookson Peirce & Co. Inc.

Cookson Peirce & Co. Inc. raised its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 12.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,963 shares of the medical equipment provider’s stock after acquiring an additional 678 shares during the period. Cookson Peirce & Co. Inc.’s holdings in Intuitive Surgical were worth $2,953,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Castleark Management LLC increased its position in shares of Intuitive Surgical by 3.4% during the 4th quarter. Castleark Management LLC now owns 90,469 shares of the medical equipment provider’s stock valued at $47,221,000 after purchasing an additional 2,990 shares during the period. Arlington Trust Co LLC increased its position in shares of Intuitive Surgical by 34.5% during the 1st quarter. Arlington Trust Co LLC now owns 745 shares of the medical equipment provider’s stock valued at $369,000 after purchasing an additional 191 shares during the period. Aveo Capital Partners LLC increased its position in shares of Intuitive Surgical by 37.4% during the 1st quarter. Aveo Capital Partners LLC now owns 727 shares of the medical equipment provider’s stock valued at $390,000 after purchasing an additional 198 shares during the period. Aaron Wealth Advisors LLC increased its position in shares of Intuitive Surgical by 3.2% during the 1st quarter. Aaron Wealth Advisors LLC now owns 2,509 shares of the medical equipment provider’s stock valued at $1,243,000 after purchasing an additional 78 shares during the period. Finally, Longbow Finance SA increased its position in shares of Intuitive Surgical by 132.0% during the 1st quarter. Longbow Finance SA now owns 19,699 shares of the medical equipment provider’s stock valued at $9,756,000 after purchasing an additional 11,209 shares during the period. Institutional investors own 83.64% of the company’s stock.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, EVP Myriam Curet sold 4,500 shares of the business’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $492.48, for a total value of $2,216,160.00. Following the completion of the sale, the executive vice president owned 353 shares of the company’s stock, valued at $173,845.44. The trade was a 92.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gary S. Guthart sold 2,800 shares of the business’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $495.24, for a total value of $1,386,672.00. Following the completion of the sale, the insider directly owned 18,520 shares of the company’s stock, valued at $9,171,844.80. This represents a 13.13% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 15,859 shares of company stock valued at $7,908,248. Insiders own 0.70% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ISRG shares. Barclays lowered their price target on Intuitive Surgical from $684.00 to $635.00 and set an “overweight” rating on the stock in a research report on Thursday, April 24th. Truist Financial lifted their price target on Intuitive Surgical from $590.00 to $600.00 and gave the company a “buy” rating in a research report on Wednesday, July 23rd. UBS Group lifted their price target on Intuitive Surgical from $547.00 to $585.00 and gave the company a “neutral” rating in a research report on Wednesday, July 23rd. Robert W. Baird lowered their price target on Intuitive Surgical from $600.00 to $575.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 23rd. Finally, Royal Bank Of Canada lifted their target price on Intuitive Surgical from $605.00 to $615.00 and gave the stock an “outperform” rating in a report on Wednesday, July 23rd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $595.95.

Intuitive Surgical Trading Up 0.9%

ISRG opened at $482.35 on Thursday. The stock has a market cap of $172.91 billion, a price-to-earnings ratio of 67.27, a PEG ratio of 5.01 and a beta of 1.59. Intuitive Surgical, Inc. has a 1 year low of $425.00 and a 1 year high of $616.00. The stock has a fifty day moving average price of $511.91 and a 200 day moving average price of $526.80.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.93 by $0.26. The firm had revenue of $2.44 billion during the quarter, compared to analysts’ expectations of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%. The business’s revenue for the quarter was up 21.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.78 earnings per share. As a group, sell-side analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.